fludarabine has been researched along with nutlin-3a in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreeff, M; Kojima, K; Konopleva, M; McQueen, T; O'Brien, S; Plunkett, W | 1 |
| Barbarotto, E; Celeghini, C; Corallini, F; Fadda, R; Grill, V; Mischiati, C; Rimondi, E; Vaccarezza, M | 1 |
| Fan, L; Fang, C; Li, JY; Liu, L; Xu, W; Yang, S; Zhang, LN; Zou, ZJ | 1 |
| Fan, L; Li, JY; Liu, L; Wang, DM; Xu, W; Yang, S; Zhang, LN; Zou, ZJ | 1 |
| Derks, IA; Eldering, E; Geisler, CH; Hüllein, J; Jethwa, A; Kater, AP; Lodén, M; Malcikova, J; Moerland, PD; Monsuur, H; Navrkalova, V; Oldreive, C; Pospisilova, S; Skowronska, A; Stankovic, T; Te Raa, GD; Trbusek, M; van Laar, J; van Oers, MH; Zenz, T | 1 |
5 other study(ies) available for fludarabine and nutlin-3a
| Article | Year |
|---|---|
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cells, Cultured; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Transcription, Genetic; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2006 |
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Blast Crisis; Cell Cycle; Cell Line, Tumor; Chlorambucil; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperazines; Proto-Oncogene Proteins c-mdm2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Vidarabine | 2008 |
S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Topics: Aged; Animals; Antineoplastic Agents; Cell Cycle Proteins; Female; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Nuclear Proteins; Piperazines; Prognosis; Protein Splicing; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Suppressor Protein p53; Vidarabine | 2012 |
Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomal Proteins, Non-Histone; Female; Humans; Imidazoles; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleoproteins; Oncogene Proteins; Piperazines; Poly-ADP-Ribose Binding Proteins; Prognosis; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2012 |
The impact of SF3B1 mutations in CLL on the DNA-damage response.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cohort Studies; DNA Damage; DNA Mutational Analysis; Doxorubicin; Flow Cytometry; Gene Deletion; Gene Expression Regulation, Leukemic; Genome, Human; Histones; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phosphoproteins; Piperazines; Prognosis; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Tumor Suppressor Protein p53; Vidarabine | 2015 |